Connect Biopharma (CNTB) reported second-quarter 2026 financial results and said enrollment was completed in its Phase 2 Seabreeze STAT asthma and COPD studies evaluating rademikibart for acute exacerbations.
The company expects topline results from both Phase 2 studies in September 2026 and said its cash, cash equivalents and short-term investments of $31.5 million as of June 30, 2026, are expected to fund operations for at least one year from the release date.
- License and collaboration revenue was $2.8 million for the three months ended June 30, 2026, compared with $48,000 a year earlier.
- Net loss was $17.3 million, or $0.27 per share, compared with $12.9 million, or $0.23 per share, in the same period of 2025.
- Research and development expense rose to $16.3 million from $8.8 million a year earlier.
- General and administrative expense was $4.1 million, down from $4.7 million in the prior-year period.
- The Phase 2 Seabreeze STAT asthma study enrolled 160 participants, while the COPD study enrolled 159 participants.
- Connect initiated the Phase 2 Seabreeze STAT IV study in August 2026 to evaluate intravenous rademikibart in 40 participants with asthma or COPD.
$CNTB Insider Trading Activity
$CNTB insiders have traded $CNTB stock on the open market 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $CNTB stock by insiders over the last 6 months:
- JAMES HUANG purchased 1,160,000 shares for an estimated $4,002,000
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$CNTB Hedge Fund Activity
We have seen 32 institutional investors add shares of $CNTB stock to their portfolio, and 11 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- 683 CAPITAL MANAGEMENT, LLC added 900,000 shares (+inf%) to their portfolio in Q1 2026, for an estimated $2,358,000
- BLACKROCK, INC. added 871,653 shares (+inf%) to their portfolio in Q2 2026, for an estimated $2,074,534
- ADAR1 CAPITAL MANAGEMENT, LLC added 742,400 shares (+inf%) to their portfolio in Q1 2026, for an estimated $1,945,088
- IKARIAN CAPITAL, LLC added 600,000 shares (+12.5%) to their portfolio in Q1 2026, for an estimated $1,572,000
- MILLENNIUM MANAGEMENT LLC added 427,551 shares (+908.7%) to their portfolio in Q1 2026, for an estimated $1,120,183
- STONEPINE CAPITAL MANAGEMENT, LLC added 310,000 shares (+inf%) to their portfolio in Q1 2026, for an estimated $812,200
- GEODE CAPITAL MANAGEMENT, LLC added 225,325 shares (+701.3%) to their portfolio in Q2 2026, for an estimated $536,273
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
